This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Queen's University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $911,116
Translating synthetic lethality with common driver events into targeted therapies for high fatality cancers
CIHR · 2021 · Nominated PI
- $765,000
Targeting TGF-beta signaling to achieve durable therapy responses in preclinical ovarian cancer models
CIHR · 2020 · Nominated PI
- $443,700
MyD88-dependent modulation of host response to insulin infusion cannulas
CIHR · 2018 · Co-investigator
Translating synthetic lethality with common driver events into targeted therapies for high fatality cancers
Principal investigators: Craig, Andrew W; Babak, Tomas
Keywords: Cancer; Crispr/Cas9; Driver Mutations; Genome-Wide Screening; Patient-Derived Xenograft Models; Synthetic Lethality; Targeted Therapy; Tumour Xenograft Models
Targeting TGF-beta signaling to achieve durable therapy responses in preclinical ovarian cancer models
Principal investigators: Craig, Andrew W
Keywords: Chemoresistance; Combination Therapies; Immunotherapy; Metastasis; Ovarian Cancer; Syngeneic Tumour Models; Tgf Beta; Tumour Microenvironment
MyD88-dependent modulation of host response to insulin infusion cannulas
Principal investigators: Fitzpatrick, Lindsay
Keywords: Continuous Subcutaneous Insulin Infusion; Diabetes; Fibroblast; Fibrosis; Foreign Body Reaction; Inflammation; Macrophage; Myd88; Teflon; Toll-Like Receptors
Development of antibody-drug conjugates that use actin-targeting warheads
Principal investigators: Allingham, John
Development of antibody-drug conjugates that use actin-targeting warheads
Principal investigators: Allingham, John S; Craig, Andrew W; Evans, P A
Keywords: Actin; Antibody; Cancer; Cytotoxic Natural Products; Drug Design; Her2 Overexpression; Metastasis; Pharmacophore; Synthtic Chemistry; Tumour-Associated Antigen
Preclinical Development of Natural Product-Based Agents as Anti-Cancer Drugs
Principal investigators: Allingham, John S; Evans, P A
Keywords: Actin; Antibodies; Cancer; Chemotherapeutic Drugs; Cytoskeleton; Drug Design; Metastasis; Natural Products; Pharmacophore; Synthetic Chemistry
Roles of F-BAR proteins in lung cancer progression and metastases
Principal investigators: Craig, Andrew W
Keywords: Cell Invasion; Cell Migration; Endocytosis; Epidermal Growth Factor Receptor; F-Bar Proteins; Lung Cancer; Metastases; Tumour Xenograft
Regulation of mast cell activation and inflammation
Principal investigators: Craig, Andrew W
Keywords: Immunity; Inflammation; Mast Cells; Protein Kinases And Phosphorylation; Signal Transduction; Transgenic Mice
The Terry Fox Foundation Training Program in Transdiciplinary Cancer Research at CIHR
Principal investigators: Mulligan, Lois M
Keywords: Cancer; Cancer Control; Drug Development Fellowships; Graduate Students; Post Doctoral Fellows; Post Md-Fellows; Training Program; Transdisciplinary Research
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.